SANTA ANA, Calif. - November 22, 2022 - (Newswire.com)
Robinson Pharma Inc. [RPI] is pleased to announce Mr. Rick L. Beatty as its new Senior Vice President of Quality and Regulatory.
Rick L. Beatty, Ph.D. cd MS eq BS Reg A em, is an experienced and successful business leader who is highly regarded in the Dietary Supplement, personal care & cosmetics, OTC, FMD, and MLM industries for over 37 years. Mr. Beatty has held prior leadership roles as Superintendent, Chief Technical Manager, Operations Manager, Chief Metallurgist, Chief Scientist, Chief Chemist, and Head of Quality, Design and Engineering.
Rick Beatty was educated at SUU and received his graduate education at the University of Texas - Austin. Mr. Beatty's scientific education and training assisted him as he started out working within a small design team on large construction projects of over 270 million dollars in the 1980s, including the start-up and operation of over a half dozen projects. Rick consulted with large global corporations worldwide and has traveled to 50 different countries. Rick Beatty once served as Chief Science Officer for the 3rd wealthiest man in the world in the 1980s. Additionally, he scored 2nd in the USA in national graduate school chemistry exams, with offers from MIT, Cal Tech, Notre Dame, UT-Austin, and many others. Rick has other education certificates from varied institutions, including the University of Wisconsin - Madison College of Engineering. Mr. Beatty has been recognized in Strathmore's Who's Who in Leadership and Business, Who's Who in American Universities and Colleges; Who's Who in Manufacturing; Rick received a Special Recognition Award from Governor Scott Matheson, Utah. He was awarded the Bausch and Lomb Science Award, and was nominated as Honorary Chairman to the American Business Tax Force for tax reduction.
Born and raised in Hurricane, Utah, Rick Beatty now lives with his wife and assists his father in operating their cattle ranch in Arizona.
The combination of Rick Beatty's experience, knowledge, culture and drive makes him an ideal fit for Robinson Pharma Inc. to fuel our next stages of growth. Robinson Pharma Inc. welcomes Rick with great pleasure and enthusiasm and wishes Rick many successes in the years to come.
Contact Information:
Robinson Pharma Inc. [email protected]
7142410235
BUFFALO, N.Y. - November 30, 2022 - (Newswire.com)
POP Biotechnologies (POP BIO), a Buffalo, New York-based biopharmaceutical startup, announces the publication of an interim analysis of the Phase 2 clinical trial of EuCorVac-19, a recombinant protein vaccine displaying the SARS-CoV-2 receptor-binding domain (RBD) antigen on the immunogenic liposomes. Data from this clinical study has been published today in BMC Medicine (https://doi.org/10.1186/s12916-022-02661-1).
EuCorVac-19 is an RBD-based vaccine consisting of POP BIO's Spontaneous Nanoliposome Antigen Particle (SNAP) technology in combination with the adjuvant genetically modified E. coli Monophosphoryl Lipid A (EcML), produced by EuCorVac-19 manufacturer Eubiologics (KOSDAQ: 206650). Use of SNAP technology enables co-delivery, as opposed to co-administration, of antigen with adjuvant, packed in an immunogenic nanoparticle format free of any carrier protein.
In this Phase II clinical study, 229 participants were enrolled at five clinical sites in South Korea. Healthy adults aged 19-75 without prior exposure to COVID-19 were dosed on day 0 and day 21 between July and October 2021. The most common local adverse events were low-grade injection site tenderness and pain, while the most common systemic adverse events were low-grade fatigue, myalgia, and headache. No clinical abnormalities were detected, and no serious adverse effects were solicited by EuCorVac-19. Adverse events did not increase with the second dosing. On day 42, Spike IgG geometric mean ELISA titers were 0.8, 211, and 590 Spike binding antibody units (BAU/mL) for placebo, low-dose, and high-dose EuCorVac-19, respectively (p
The published data shows that in this trial, EuCorVac-19 was well-tolerated and induced antibodies in a dose-dependent manner that neutralizes SARS-CoV-2. The unique liposome display approach of EuCorVac-19, which lacks any immunogenic protein components besides the antigen itself, coupled with the lack of increased adverse events during boosting suggests the vaccine platform is amenable to multiple boosting regimes in the future to help control the ongoing COVID-19 pandemic.
"The results of this Phase II trial provide critical evidence of the value of the SNAP platform. This data provides invaluable support towards our platform's development, further enabling the creation of new vaccines with the potential to alleviate suffering worldwide," says POP BIO co-founder Jonathan Smyth.
"The unique qualities of the SNAP adjuvant system enabled simple conversion of protein antigens into immunogenic particles that safely induced virus-neutralizing antibodies. We look forward to further study of this technology for the prevention of COVID-19 and other diseases," says company co-founder and study co-author Jonathan Lovell.
Presently, EuCorVac-19 is undergoing two Phase III clinical studies in simultaneous studies in the Philippines and the Democratic Republic of Congo. EuBiologics is working with international research organizations to expedite recruitment and analyze trial results to accelerate regulatory approval of EuCorVac-19.
POP BIO is developing new vaccine product candidates and is seeking further collaborators around the SNAP technology to make use of the unique qualities of the vaccine platform technology.
POP Biotechnologies (POP BIO): POP BIO is a privately held biotechnology company focused on the research and development of novel therapeutics and vaccines employing their proprietary porphyrin-phospholipid (PoP) liposome technologies. The PoP technology, exclusively licensed from The State University of New York Research Foundation (SUNY-RF), was developed by company founder Dr. Jonathan Lovell at his academic facilities at The State University of New York at Buffalo (SUNY Buffalo).
POP BIO's SNAP Technology: POP BIO's Spontaneous Nanoliposome Antigen Particleization (SNAP) technology enables the rapid development and manufacturing of immunogenic particle-based vaccines and immunotherapies directed against infectious diseases and other diseases through the use of cobalt-modified variant of the PoP technology (CoPoP). The SNAP technology enables the seamless generation of stable particle formation and liposome-display of protein and peptide antigens, resulting in substantial improvements in antigen-specific immune responses.
About EuBiologics: EuBiologics is a South Korean biotechnology company that is advancing the EuCorVac-19 COVID-19 vaccine and other vaccine products. EuBiologics has two main animal-based bioreactors (1,000L) to produce recombinant protein antigens and EcML. The total capacity of COVID-19 vaccine is in the hundreds of millions of doses per year.
About EuBiologics' EuIMT Technology: EuBiologics' Immune Modulation Technology uses genetically engineered Monophosphoryl Lipid A (MLA), termed EcML, a unique TLR4 agonist. EuBiologics has IP protection around EcML and various adjuvant systems. Eubiologics' EcML and POP BIO's SNAP technologies synergize to create potent next-generation vaccines.
Contact Information:
Jonathan Smyth
President [email protected]
+13152200087
![Robinson Pharma Inc. [RPI] Announces Mr. Rick L. Beatty as Senior Vice President of Quality and Regulatory](https://cdn.newswire.com/files/x/2d/80/6c689993eb66c5b70952fe05029e.jpg "Robinson Pharma Inc. [RPI] Announces Mr. Rick L. Beatty as Senior Vice President of Quality and Regulatory")
![Robinson Pharma Inc. [RPI] Announces Mr. Rick L. Beatty as Senior Vice President of Quality and Regulatory](https://cdn.newswire.com/files/x/aa/73/20910566d80a412e1c88452b1c38.png "Robinson Pharma Inc. [RPI] Announces Mr. Rick L. Beatty as Senior Vice President of Quality and Regulatory")
